mTOR activation has been shown to be important for the secretion of VEGF [15] . Rapamycin could inhibit tumour growth [16] , progression [17] and metastasis [18] through anti-angiogenic activity related to impaired production of VEGF or inhibition of cell proliferation [19] . In HCC, total p70S6K expression was positively correlated with tumour nuclear grade, and inversely correlated with tumour size [20] . Complete remission of lung metastases [21] and tumour-free survival [22] were observed in patients on rapamycin after a liver transplant. These observations make mTOR and its downstream targets exciting novel targets for HCC therapy. mTOR inhibitors are currently in clinical trials as novel anti-cancer agents [23] [24] [25] . [26] . RAD001 is efficacious in both preclinical and clinical transplant trials [27] . RAD001 therapy was shown to inhibit the growth of cell lines [28] and tumour growth [29] , improve the efficacy of replicating adenoviruses that target colon cancer [30] , block the cell cycle [31] and sensitize tumour cells to cisplatin-induced apoptosis [32] .
RAD001 (Everolimus) is a novel mTOR inhibitor that exhibits improved aqueous solubility for oral administration
In the present study, we report that RAD001 potently inhibited tumour growth through inhibition of downstream targets of mTOR, angiogenesis and positive cell cycle regulators. 
Material and methods

Reagents
Results
We first investigated mTOR signalling in four patient-derived HCC xenografts. Figure 1 (Fig. 2B-D Figure 5 , high levels of VEGF were detected in sera collected from vehicle-treated mice and VEGF levels were significant lower in the sera derived from RAD001-treated animals (P < 0. [44, 45] . As shown in Figure 2 [53] . This appears to be a consequence of increased stability of IRS-1 and up-regulation of the IGF-1 signalling pathway [53] . In the present study, up-regulation of phospho-Akt is not observed in RAD001-treated tumours (Fig. 4) 
01). Low circulating VEGF was observed in mice bearing 30-1004 xenograft. This correlates well with the number of VEGF-positive cells in this tumour.
Discussion
It is well known that HCC is highly resistant to available chemotherapy agents, administered either alone or in combination [38]. Since downstream targets of mTOR are activated in HCC [20] and given that the mTOR pathway can be activated by a number of growth factors, receptor tyrosine kinases [39, 40] and HCV replication [41], inhibition of this pathway could have profound effects on the development and progression of HCC. We previously report the characterization of HCC xenografts established directly from human HCC tumours [33]. The advantages of patient-derived xenografts as opposed to xenograft derived from cell lines include the fact that they retain both tumour cells as well as stromal cells and have intact
